TG Therapeutics is a clinical-stage biopharmaceutical company engaged in acquiring, developing and commercializing pharmaceutical products that are medically important for the treatment of cancer and other underserved therapeutic needs. The company is currently developing two advanced therapies to target hematological malignancies, TG-1101 and TGR-1202. The company’s headquarters are located in New York City. For more information, visit the company’s Web site at www.tgtherapeutics.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: